Healthcare Industry News: histone deacetylase
News Release - September 26, 2007
EnVivo Pharmaceuticals Announces Executive AppointmentDr. Dana C. Hilt Named SVP, Clinical Development & Chief Medical Officer
WATERTOWN, Mass., Sept. 26 (HSMN NewsFeed) -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced the appointment of Dr. Dana C. Hilt as Senior Vice President and Chief Medical Officer. He will be responsible for coordinating all pre-clinical and clinical development activities of EnVivo's growing pipeline.
Dr. Hilt, 55, previously served as Senior Vice President, Clinical Research and Medical Affairs & Chief Medical Officer for Critical Therapeutics in Lexington, Massachusetts. Dr. Hilt is a distinguished neurologist with extensive drug development experience from his tenures at Amgen, Guilford Pharmaceuticals and Ascend Therapeutics. In addition, he has held both scientific and professorial positions with the University of Southern California School of Medicine, the National Institutes of Health and the University of Maryland School of Medicine where he was a clinical Associate Professor in the department of Neurology. At the beginning of his career, he was a Resident Fellow in Neurology at the Johns Hopkins University School of Medicine and interned at Harvard University Medical School.
Dr. Hilt is a member of the American Academy of Neurology, Movement Disorders Society, American Society for Experimental Neurotherapeutics, American Association for the Advancement of Science, Society for Neuroscience and Endocrine Society. He is the author of over 50 publications. Dr. Hilt received his Bachelor of Science Degree in Chemistry (with Distinction) from the University of Maine and an M.D. from the Tufts University School of Medicine.
"Given the continuing growth of EnVivo's pre-clinical and clinical programs in the field of neuro-degenerative diseases, Dana brings critically important skills to the management team. His deep expertise in drug development will be of increasing importance as we progress our pipeline and are seeking to further broaden our pipeline in the next two years," said Kees Been, President and Chief Executive Officer.
EnVivo Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders including, Alzheimer's disease, Parkinson's disease, Huntington's disease and Spino Cerebellar Ataxias. The company's lead programs include a Nicotinic Acetylcholine Receptor Agonist Program (alpha-7) for Alzheimer's disease and Schizophrenia, a histone deacetylase (HDAC) program for Huntington's disease, EVP2442 program for neuron-protection and the PDE10 inhibitor and gamma- secretase modulator programs. For more information see http://www.envivopharma.com
Source: EnVivo Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.